This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PF-00734200, gosogliptin, SATYOR
Description: PF-00734200 is a DPP-IV inhibitor.
Deal Structure: PF-00734200 was originally developed by Pfizer.
Pfizer and ChemRar
In June 2012, Pfizer and ChemRar High Tech Center (ChemRar) announced an agreement under which Pfizer grants the ChemRar group company SatRx exclusive rights to PF-00734200. Under the agreement, Pfizer has granted worldwide exclusive rights (except China) to SatRx for development, manufacturing, regulatory submission, and commercialization of the DPPIV molecule alone and in combination with certain classes of molecules. If approved and commercialized, Pfizer will receive royalties and milestone payments from SatRx. The agreement was executed following the signing of a Memorandum of Understanding (MoU) in March 2011, under which Pfizer and ChemRar agreed to explore a collaboration focused on research, development and commercialization of innovative compounds and vaccines to treat patients with cardiometabolic, infectious and oncology diseases in Russia and other countries.
Partners: Pfizer Inc.
Additional information available to subscribers only: